Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.

July 12, 2024

Vol.50 No.28

Conversation with The Cancer Letter

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

A phase II trial evaluating setanaxib, Calliditas Therapeutics AB’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck shows positive topline results.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Community cancer care linked with poorer outcomes for some head/neck cancers

Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to survive, according to new research by investigators from the Johns Hopkins Kimmel Cancer Center and its Head and Neck Cancer Center.

January 05, 2024

Vol.50 No.01

Clinical Roundup

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Researchers from University of Pittsburgh and Washington University School of Medicine in St. Louis found that liquid from surgical drains, which is usually tossed in the trash, could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus.

January 05, 2024

Vol.50 No.01

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

YOU MAY BE INTERESTED IN

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

Community cancer care linked with poorer outcomes for some head/neck cancers

Novel liquid biopsy of lymph fluid could guide precision treatment for head and neck cancer

Renew today!

Subscriber content

Login